1/15
11:06 am
regn
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]
Low
Report
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]
1/15
06:42 am
regn
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]
Low
Report
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]
1/14
07:36 pm
regn
BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]
Low
Report
BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]
1/14
03:53 am
regn
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]
Low
Report
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]
1/13
07:52 pm
regn
Regeneron CEO: AI is as good as the data it can train on [CNBC]
Low
Report
Regeneron CEO: AI is as good as the data it can train on [CNBC]
1/13
10:20 am
regn
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]
Low
Report
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]
1/11
08:40 pm
regn
A big Wall Street flip just changed the Regeneron narrative [Yahoo! Finance]
Medium
Report
A big Wall Street flip just changed the Regeneron narrative [Yahoo! Finance]
1/10
05:43 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/10
01:07 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall
Medium
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall
1/8
12:49 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Truist Financial Corporation from $798.00 to $820.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Truist Financial Corporation from $798.00 to $820.00. They now have a "buy" rating on the stock.
1/7
05:38 pm
regn
Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN) [Yahoo! Finance]
Low
Report
Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN) [Yahoo! Finance]
1/7
12:53 pm
regn
REGN vs. ILMN: Which Stock Is the Better Value Option? [Yahoo! Finance]
Low
Report
REGN vs. ILMN: Which Stock Is the Better Value Option? [Yahoo! Finance]
1/7
12:45 pm
regn
Why Regeneron (REGN) Stock Is Trading Up Today [Yahoo! Finance]
Low
Report
Why Regeneron (REGN) Stock Is Trading Up Today [Yahoo! Finance]
1/7
11:12 am
regn
Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says [Yahoo! Finance]
1/7
08:02 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "buy" rating. They now have a $860.00 price target on the stock, up previously from $627.00.
Medium
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "buy" rating. They now have a $860.00 price target on the stock, up previously from $627.00.
1/4
03:39 pm
regn
Regeneron (REGN) Valuation Check After Japan Clears Dupixent for Pediatric Severe Asthma Expansion [Yahoo! Finance]
Low
Report
Regeneron (REGN) Valuation Check After Japan Clears Dupixent for Pediatric Severe Asthma Expansion [Yahoo! Finance]
1/2
04:05 pm
regn
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
Low
Report
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
1/2
10:22 am
regn
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? [Yahoo! Finance]
Low
Report
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? [Yahoo! Finance]
12/30
04:14 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
12/29
08:12 am
regn
3 Cash-Heavy Stocks We Approach with Caution [Yahoo! Finance]
Low
Report
3 Cash-Heavy Stocks We Approach with Caution [Yahoo! Finance]
12/29
06:08 am
regn
Revamping best-selling drugs to combat patent cliff has limits [Yahoo! Finance]
Low
Report
Revamping best-selling drugs to combat patent cliff has limits [Yahoo! Finance]
12/26
11:37 pm
regn
Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) [Yahoo! Finance]
Low
Report
Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) [Yahoo! Finance]
12/23
12:52 pm
regn
Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic [Yahoo! Finance]
Low
Report
Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic [Yahoo! Finance]
12/23
01:00 am
regn
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Low
Report
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
12/22
04:05 pm
regn
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference